Thinking downstream to accelerate the introduction of new vaccines for developing countries

Vaccine

Volumn 21, Issue SUPPL. 2, 2003, Pages

  Clemens, John D ^a  

^a Seoul National University   (South Korea)

Author keywords

Developing countries; Translational research; Vaccination

Indexed keywords

BCG VACCINE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; MALARIA VACCINE; VACCINE;

COST EFFECTIVENESS ANALYSIS; DECISION MAKING; DEVELOPING COUNTRY; DRUG MANUFACTURE; DRUG MARKETING; ECONOMIC DEVELOPMENT; HEALTH PROGRAM; HEALTH PROMOTION; HUMAN; POLICY; PRIORITY JOURNAL; SHORT SURVEY; VACCINATION;

EID: 0037987973     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(03)00210-X     Document Type: Short Survey

References (5)

1. Rappuoli R., Miller H.I., Falkow S. The intangible value of vaccination. Science. 297:2002;937-940.
2. Institute of Medicine. Diseases of importance in developing countries. In: New vaccine development. Establishing priorities, vol. II. Washington, DC: National Academy Press; 1986. p. 241.
3. Clemens J.D., Brenner R., Rao M. Evaluating new vaccines for developing countries: efficacy or effectiveness? J. Am. Med. Assoc. 275:1996;390-397.
4. Muraskin W. War against hepatitis B: a history of the International Task Force on Hepatitis B immunization. Philadelphia: University of Pennsylvania Press; 1995.
5. Clemens JD, Koo H-W. Trial design for vaccines. Part B. Phase 3 studies of vaccines. In: Bloom BR, Lambert P-H, editors. The vaccine book. New York: Elsevier; 2003. p. 95-117.